Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes

Thrombosis and Haemostasis

Volumn 111, Issue 3, 2013, Pages 438-446

  Segers, Olivier ^a   Simioni, Paolo ^b   Tormene, Daniela ^b   Castoldi, Elisabetta ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Factor V Leiden; Intermediate phenotype; Single nucleotide polymorphism; Thrombin generation; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; CALIBRATED AUTOMATED THROMBOGRAPHY; CARDIOVASCULAR RISK; ENDOGENOUS THROMBIN POTENTIAL; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HAPLOTYPE; HEMATOLOGICAL PROCEDURE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBIN GENERATION; VENOUS THROMBOEMBOLISM;

FACTOR V LEIDEN; INTERMEDIATE PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBIN GENERATION; VENOUS THROMBOEMBOLISM;

ADULT; ANTITHROMBIN III; FACTOR V; FACTOR X; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; ITALY; LIPOPROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN S; PROTHROMBIN; THROMBIN; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84897070166     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-05-0360     Document Type: Article

References (50)

1. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
2. Simone B, De Stefano V, Leoncini E, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol 2013; 28: 621-647.
3. Kalafatis M, Bertina RM, Rand MD, et al. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4053-4057.
4. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-21166.
5. Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93: 2552-2558.
6. Castoldi E, Brugge JM, Nicolaes GA, et al. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004; 103: 4173-4179.
7. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
8. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-650.
9. Heit JA, Sobell JL, Li H, et al. The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. J Thromb Haemost 2005; 3: 305-311.
10. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
11. Simioni P, Castoldi E, Lunghi B, et al. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood 2005; 106: 2363-2365.
12. Mingozzi F, Legnani C, Lunghi B, et al. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers. Thromb Haemost 2003; 89: 983-989.
13. Segers O, Simioni P, Tormene D, et al. Genetic modulation of the FV Leiden/ normal FV ratio and risk of venous thrombosis in FV Leiden heterozygotes. J Thromb Haemost 2012; 10: 73-80.
14. Tosetto A, Rodeghiero F, Martinelli I, et al. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. Br J Haematol 1998; 103: 871-876.
15. Meinardi JR, Middeldorp S, de Kam PJ, et al. Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis. Blood Coagul Fibrinolysis 2001; 12: 713-720.
16. Medina P, Navarro S, Estellés A, et al. Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden. Thromb Haemost 2005; 94: 389-394.
17. Miñano A, Ordóñez A, España F, et al. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica 2008; 93: 729-734.
18. Smith NL, Hindorff LA, Heckbert SR, et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. J Am Med Assoc 2007; 297: 489-498.
19. Bezemer ID, Bare LA, Doggen CJ, et al. Gene variants associated with deep vein thrombosis. Jama 2008; 299: 1306-1314.
20. Germain M, Saut N, Greliche N, et al. Genetics of venous thrombosis: insights from a new genome wide association study. PLoS One 2011; 6: e25581.
21. Plomin R, Haworth CM, Davis OS. Common disorders are quantitative traits. Nat Rev Genet 2009; 10: 872-878.
22. Wichers IM, Tanck MW, Meijers JC, et al. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thromb Haemost 2009; 101: 465-470.
23. Segers O, van Oerle R, ten Cate H, et al. Thrombin generation as an intermediate phenotype for venous thrombosis. Thromb Haemost 2010; 103: 114-122.
24. Brandts A, van Hylckama Vlieg A, Rosing J, et al. The risk of venous thrombosis associated with a high endogenous thrombin potential in the absence and presence of activated protein C. J Thromb Haemost 2007; 5: 416-418.
25. Dargaud Y, Trzeciak MC, Bordet JC, et al. Use of calibrated automated thrombinography +/-thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006; 96: 562-567.
26. van Hylckama Vlieg A, Christiansen SC, Luddington R, et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007; 138: 769-774.
27. Tripodi A, Martinelli I, Chantarangkul V, et al. The endogenous thrombin potential and the risk of venous thromboembolism. Thromb Res 2007; 121: 353-359.
28. ten Cate-Hoek AJ, Dielis AW, Spronk HM, et al. Thrombin generation in patients after acute deep-vein thrombosis. Thromb Haemost 2008; 100: 240-245.
29. Hron G, Kollars M, Binder BR, et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. J Am Med Assoc 2006; 296: 397-402.
30. Eichinger S, Hron G, Kollars M, et al. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 2008; 54: 2042-2048.
31. Besser M, Baglin C, Luddington R, et al. High rate of unprovoked recurrent venous thrombosis is associated with a high thrombin generating potential in a prospective cohort study. J Thromb Haemost 2008; 6: 1720-1725.
32. Tripodi A, Legnani C, Chantarangkul V, et al. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008; 6: 1327-1333.
33. Lutsey PL, Folsom AR, Heckbert SR, et al. Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2009; 7: 1639-1648.
34. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
35. Castoldi E, Maurissen LF, Tormene D, et al. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica 2010; 95: 1563-1571.
36. Dielis AW, Castoldi E, Spronk HM, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-131.
37. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
38. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
39. Ceelie H, Bertina RM, van Hylckama Vlieg A, et al. Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 2001; 85: 1066-1070.
40. Castoldi E, Simioni P, Tormene D, et al. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost 2007; 5: 971-979.
41. Martinelli I, Battaglioli T, Tosetto A, et al. Prothrombin A19911G polymorphism and the risk of venous thromboembolism. J Thromb Haemost 2006; 4: 2582-2586.
42. Chinthammitr Y, Vos HL, Rosendaal FR, et al. The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA study, a large population-based case-control study. J Thromb Haemost 2006; 4: 2587-2592.
43. Antón AI, Teruel R, Corral J, et al. Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. Haematologica 2009; 94: 589-592.
44. Bertina RM, Ploos van Amstel HK, van Wijngaarden A, et al. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood 1990; 76: 538-548.
45. Moatti D, Seknadji P, Galand C, et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol 1999; 19: 862-869.
46. Giri TK, Yamazaki T, Sala N, et al. Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. Blood 2000; 96: 523-531.
47. Arnaud E, Moatti D, Emmerich J, et al. No link between the TFPI V264M mutation and venous thromboembolic disease. Thromb Haemost 1999; 82: 159-160.
48. Amini-Nekoo A, Futers TS, Moia M, et al. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 113: 537-543.
49. Van Dreden P, Grosley M, Cost H. Total and free levels of tissue factor pathway inhibitor: a risk factor in patients with factor V Leiden? Blood Coagul Fibrinolysis 1999; 10: 115-116.
50. Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 27852-27858.